SAR444559

SAR444559 is an investigational monoclonal antibody targeting CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1), developed by Sanofi. CD38 is a cell-surface protein highly expressed on plasma cells and other immune cell subsets, where it functions as both a receptor and an enzyme involved in calcium signaling. By inhibiting CD38, SAR444559 is intended to deplete or modulate pathogenic immune cells in the context of autoimmune disorders. The drug has undergone Phase 1 clinical evaluation in healthy volunteers to characterize its safety, tolerability, and pharmacokinetics following subcutaneous administration.